Dexcom (DXCM)

Executive Summary

Dexcom Inc. is the leading continuous glucose monitoring (CGM) company, with a market cap of $24.44B. Its core products include real-time CGM systems for Type 1, Type 2, and gestational diabetes, as well as Stelo, an over-the-counter glucose biosensor for metabolic health. The company's technology is widely adopted globally and is the preferred CGM brand for Medicare Advantage patients. Dexcom has consistently innovated, with the G7 system offering superior accuracy and integration with automated insulin delivery systems. The company's strong commercial execution and expanding addressable market position it for sustained growth. Key growth drivers include the expansion of the Stelo OTC franchise into metabolic wellness, increased penetration in Type 2 diabetes not on insulin, and global reimbursement expansion. Partnerships with insulin pump manufacturers and digital health platforms further solidify its ecosystem. Despite competition from Abbott and Medtronic, Dexcom's technological edge and brand loyalty underpin its market leadership. Regulatory tailwinds include potential FDA labels for non-adjunctive use and pediatric indications, which could expand the user base. The company's robust pipeline and focus on product innovation are expected to drive double-digit revenue growth over the next few years.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for next-generation CGM sensor (G8) or Stelo 2.080% success
• Q3 2026Expansion of Medicare coverage for Stelo OTC or Type 2 diabetes non-intensive users70% success
• Q1 2027Major partnership or integration with leading insulin pump manufacturer (e.g., Insulet Omnipod 5)85% success